Midatech makes board change
This article was originally published in Scrip
Midatech Pharma has announced that Jeff Brown is stepping down from its board of directors, following the company's IPO, to pursue other business interests. The change is effective from 30 April 2015. Midatech, headquartered in Oxford, UK, has a pipeline of product candidates in clinical and preclinical development in the key therapeutic areas of diabetes, cancer and neurological/ophthalmological diseases. The company floated on the AIM Market of the London Stock Exchange in December 2014.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.